Abbott Laboratories reported second-quarter revenue of $11.14 billion, edging past analysts’ $11.06 billion forecast, while adjusted earnings per share rose 10% from a year earlier to $1.26, also a shade above expectations. Organic sales increased 6.9%, driven by double-digit gains in medical devices, particularly the FreeStyle Libre glucose monitor and heart-failure therapies. GAAP earnings came in at $1.01 a share. Despite the top-line beat, the company trimmed guidance. It now expects third-quarter adjusted EPS of $1.28 to $1.32, below the $1.34 analysts project, and narrowed its full-year target to $5.10–$5.20 a share from a prior $5.05–$5.25 range. Management also pegged full-year organic sales growth at 6% to 7%, slightly under Wall Street’s 7.4% consensus, and warned of a roughly $700 million drag on 2025 diagnostics revenue as COVID-19 test sales continue to fade. The more cautious outlook overshadowed solid quarterly results: gross margin expanded by 100 basis points to an adjusted 57%, and the company highlighted continued pipeline progress, including U.S. FDA approval of its Tendyne transcatheter mitral-valve device. Still, investors focused on the guidance reset; Abbott’s shares fell as much as 5% in early New York trading Thursday.